Jul 21, 2026 · 4 min
Novartis cancer drugs and UK defense signals spark European market rally
Novartis Climbs, Mitie Soars, Babcock Up
This episode highlights how corporate innovation in healthcare and shifting geopolitical defense spending are actively reshaping European market valuations.
- 1Novartis posted higher-than-expected profits as sales of its innovative cancer treatments offset losses from older blockbuster drugs.
- 2European defense stocks rallied following positive spending signals from the UK government at the Farnborough Airshow.
- 3Defense majors including Babcock, BAE Systems, and Rheinmetall saw notable gains on the policy outlook.
Don't miss
Novartis shares climb as its strategic pivot to innovative cancer therapies successfully offsets the loss of former blockbuster drug revenues.
The brief
Swiss pharmaceutical giant Novartis is leading a European market rally after posting higher-than-expected profits, driven by a surge in demand for its innovative new cancer treatments.
The success of these next-generation oncology therapies is helping Novartis offset steep sales losses from its older blockbuster drugs as the company focuses on innovative medicine.
Meanwhile, European defense stocks are climbing following positive political signals about UK defense spending commitments coming out of the Farnborough Airshow.
Major defense players like Babcock, BAE Systems, Rheinmetall, and Leonardo are seeing gains as markets react to spending outlooks under the new UK Chancellor.
What was said on this episode
7 statements · 6 positive · 1 neutral
Novartis’s new cancer medicines generated higher-than-expected profits.
“they posted higher than expected profits from their new cancer medicines”
Listen at 0:33
Analysts believe Novartis’s patent cliff likely reached its worst point last quarter.
“analysts are saying that the last quarter probably marked kind of the worst of a patent cliff there”
Listen at 1:09
The OCS Group acquisition values Mitie at about £3.1 billion.
“the deal valuing at about £3.1 billion”
Listen at 1:47
The OCS Group offer represented about a 45% premium to Mitie’s prior closing price.
“it's about a 45% premium to MITI's closing price yesterday”
Listen at 2:19
Babcock led European defense-stock gains, rising as much as 7%.
“Babcock's leading those gains amongst defence stocks, so up as much as 7%”
Listen at 2:48
Signals about defense commitments are boosting defense stocks.
“So this is boosting stocks.”
Listen at 3:18
Markets view Healey as very likely to increase defense spending.
“it's being seen as very likely that he'll boost fence spending”
Listen at 3:23
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Mentioned
Bloomberg Audio Studios
EuropeBooks & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.